Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.04 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.27 +11.9% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.51 +1.2% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0% S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.04 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.27 +11.9% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.51 +1.2% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0%
M&A / Property

UPDATE OF THE TRANSACTION ANNOUNCED ON NOVEMBER 25, 2025, FOR THE ACQUISITION OF THE MINORITY INTEREST IN THE SUBSIDIARY GROUPE TECHNOLOGIQUE KDA INC.

By The Northwire Desk — AI Analysis Dec 24, 2025 · 11:00 KDA · 0.24 KDA Group Inc.
KDA · Price

Executive Summary

  • KDA Group Inc. entered into a share‑transfer agreement to acquire a 20 % interest in its subsidiary Groupe Technologique KDA Inc. (“GTK”) from ERxpert Inc., issuing 35,000,000 KDA common shares as consideration.
  • The transaction received conditional approval from the TSX Venture Exchange on December 18 2025; final approval is contingent on filing required documents by January 20 2026.
  • Completion of the acquisition will increase KDA’s ownership in GTK and consolidate its control over the subsidiary’s technology‑focused healthcare SaaS operations.

Key Details

  • Transaction Structure: Share transfer agreement – ERxpert transfers all of its GTK shares to KDA; KDA issues 35 million common shares to ERxpert as payment.
  • Interest Acquired: 20 % of the issued and outstanding shares of GTK (the subsidiary).
  • Consideration: 35,000,000 KDA common shares (no cash component disclosed).
  • Regulatory Status: Conditional approval from TSX Venture Exchange received on 2025‑12‑18. Final approval requires filing of requested documents/information by 2026‑01‑20; final acceptance will be issued after satisfactory review.
  • Strategic Rationale (implied): Enhances KDA’s ownership and control over GTK, aligning the subsidiary more closely with KDA’s overall SaaS healthcare strategy.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from KDA Group Inc.

Jun 18, 2026 · 13:15

Clinical validation of Medherize confirms value prop, but tiny revenue and depleted cash demand urgent capital raise.

Other May 29, 2026 · 18:00

KDA Group Settles Debt with Equity Amidst Share Price Collapse

Financings May 05, 2026 · 13:30

Governance Cleanup Amidst Valuation Trough

Regulatory Dec 03, 2025 · 10:30

KDA GROUP ANNOUNCES PARTNERSHIP AGREEMENT WITH CHU DE QUEBEC-UNIVERSITE LAVAL FOR THE DEPLOYMENT OF MEDHERIZE

M&A / Property Dec 01, 2025 · 13:45

KDA GROUP DEPLOYS MEDHERIZE ACROSS COMMUNITY PHARMACIES: A MAJOR STEP FORWARD IN THE MANAGEMENT OF ORAL ANTICANCER THERAPIES

Production / Operations Nov 25, 2025 · 15:00

KDA GROUP ANNOUNCES AGREEMENT TO ACQUIRE MINORITY INTEREST IN ITS SUBSIDIARY GROUPE TECHNOLOGIQUE KDA INC.

M&A / Property